In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner.
Energy Transfer Partners takes on Celgene for this first round-robin match up in our search for the better stock today.
Joel South, energy analyst at The Motley Fool, thinks Energy Transfer Partners (ETP) is a great investment for dividend lovers. The Master Limited Partnership currently distributes a very respectable 6.6% yield, but with strong segment diversification, a proven track record of executing on project backlogs and a built out pipeline infrastructure ready to service U.S. LNG exports, distributable cash flows should continue to pick up for unitholders.
Healthcare Analyst David Williamson believes the number one reason Celgene (CELG) should win this match is its ability to open new sales possibilities for already approved drugs. By expanding indications, i.e. having drugs used for multiple diseases, management expects to double earnings from 2013 to 2017. Headlined by megablockbuster Revlimid, this big biotech is an oncology and autoimmune powerhouse's stock is showing no signs of slowing down.
Vote here to determine the winner of this match and sound off in the comments. Check back to Fool.com to see who advances in the tournament.
